Literature DB >> 29697471

Roles for active surveillance in renal cancer.

Jaime O Herrera-Caceres1, Michael A S Jewett.   

Abstract

PURPOSE OF REVIEW: With this review, we describe the most recent advances in active surveillance as well as diagnosis and management of small renal masses (SRMs). RECENT
FINDINGS: We discuss diagnosis, differentiation of solid from cystic lesions, risk prediction and treatment of the SRM. A better understanding of the disease facilitates the use of more conservatory treatments, such as active surveillance. Active surveillance has been increasingly accepted not only for SRM, but also for larger tumors and even metastatic patients. Exiting advances in risk prediction will help us define which patients can be safely managed with active surveillance and which require immediate treatment. Meanwhile, the use of renal tumor biopsies is still an important tool for these cases.
SUMMARY: Active surveillance is an option for many patients with renal masses. Noninvasive methods for diagnosis and risk prediction are being developed, but meanwhile, renal tumor biopsy is a useful tool. A better understanding of the disease increases the number of patients who can undergo active surveillance fully certain of the safety of their management.

Entities:  

Mesh:

Year:  2018        PMID: 29697471     DOI: 10.1097/MOU.0000000000000506

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  3 in total

1.  Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under "Active Surveillance" for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort Study.

Authors:  Vittorio Fasulo; Marco Paciotti; Massimo Lazzeri; Roberto Contieri; Paolo Casale; Alberto Saita; Giovanni Lughezzani; Pietro Diana; Nicola Frego; Pier Paolo Avolio; Piergiuseppe Colombo; Grazia Maria Elefante; Giorgio Guazzoni; Nicolò Maria Buffi; Michael Bates; Rodolfo Hurle
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

Review 2.  Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma.

Authors:  Bryce R Christensen; Yasmin M Hajja; Vadim Koshkin; Pedro C Barata
Journal:  Curr Treat Options Oncol       Date:  2021-01-12

Review 3.  Circulating RNA in Kidney Cancer: What We Know and What We Still Suppose.

Authors:  Alessandra Cinque; Riccardo Vago; Francesco Trevisani
Journal:  Genes (Basel)       Date:  2021-05-28       Impact factor: 4.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.